Blocking two cancer pathways may curb medulloblastoma relapse, preclinical study suggests

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% of patients will see their cancer return, and once it does, outcomes are often devastating.

Continue Reading this article here